Balaxi Pharmaceuticals (BALAXI) Q2 24/25 earnings summary

Executive summary

• Focuses on branded IPR-driven pharma in frontier markets, with leadership in Latin America and Africa and a strong branded generics portfolio.

• Transitioning from an asset-light to asset-right model by establishing its first manufacturing facility in Hyderabad, targeting backward integration and global expansion.

• Approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2024.

• Operations span 8 countries, with 1010 registered products and 700+ in the pipeline as of September 30, 2024.

• Company Secretary and Compliance Officer resigned, with a new appointment effective November 6, 2024.

Financial highlights

• Q2 FY25 revenue rose 41.4% year-over-year to ₹77.38 crore; gross profit up 29.7% to ₹33.21 crore.

• Consolidated revenue from operations for H1 FY25 was ₹14,300.38 lakhs, up from ₹12,047.63 lakhs year-over-year.

• Q2 FY25 PAT was ₹4.59 crore, down 68.2% year-over-year; PAT margin fell to 5.9%.

• FY24 revenue declined 28.3% year-over-year to ₹241.29 crore; gross margin improved by 690 bps to 46.7%.

• FY24 PAT was negative at ₹(2.39) crore, compared to ₹45.96 crore in FY23, impacted by currency devaluation in Angola.

Outlook and guidance

• Commercial production at the Hyderabad facility is expected to begin by June 2025, supporting backward integration and new market opportunities.

• Anticipates substantial market share growth driven by product registrations and expansion in existing and new markets.

• Financial statements reviewed and approved by the Board, with no material misstatements identified by auditors.